In the relentless battle against cancer, precision is power. Modern oncology demands not just treatments but smarter, faster, and more accurate ways to detect disease, determine therapy, and monitor treatment response. As the global diagnostics industry races to innovate, a handful of visionary firms are redefining what early detection and cancer diagnostics can mean for patient outcomes and healthcare systems worldwide.
Among these trailblazers is Creatv MicroTech, Inc., a company at the forefront of next-generation cancer diagnostics. Under the leadership of Dr. Cha-Mei Tang, President and CEO, the firm is pioneering transformative technologies that promise to make novel cancer diagnostics more accessible, accurate, and actionable. By merging advanced science with a clear mission to save lives, Creatv MicroTech isn’t just participating in the diagnostics revolution — it’s helping shape its future.
The Genesis of Creatv Bio, a division of Creatv MicroTech, Inc.
The foundation of Creatv MicroTech, Inc. was born from a convergence of expertise, curiosity, and an unwavering commitment to solving real-world challenges. With a strong background in electrical engineering and a distinguished career in theoretical physics, Cha-Mei Tang recognized the potential of advanced microfabrication technologies to create meaningful breakthroughs.
What began as a focused effort to improve X-ray imaging through the development of precision anti-scatter grids to reduce scattered X-rays soon evolved into a journey of innovation with far-reaching implications. Leveraging collaborations with institutions like Argonne National Laboratory, the company built a reputation for cutting-edge microfabrication solutions.
The true turning point came when a client requested specialized microfilters for capturing circulating tumor cells (CTCs). Although the original project was discontinued, Creatv MicroTech’s team chose to explore the potential of these microfilters. This decision sparked a transformative shift—leading to groundbreaking research in cancer diagnostics and laying the foundation for the company’s flagship innovations that are now reshaping the future of liquid biopsy and cancer detection. This started the journey of Creatv Bio.
Redefining Cancer Diagnostics with Breakthrough Biomarkers
Creatv Bio stands apart in the cancer diagnostics industry by introducing an entirely new dimension to liquid biopsy technology. The company’s groundbreaking discovery of Cancer-Associated Macrophage-like Cells (CAMLs) has unlocked diagnostic possibilities that were previously unexplored. Unlike traditional circulating tumor cell (CTC) detection, which often limits its application to late-stage cancers of four cancers, the identification and characterization of CAMLs have enabled the company to deliver highly sensitive diagnostics that detect cancer presence and progression at all stages across multiple cancer types.
Under the leadership of Dr. Cha-Mei Tang, Creatv Bio leveraged its expertise in advanced microfabrication to create proprietary platforms that combine precision engineering with innovative biology. This unique integration allows for the consistent capture and analysis of rare cells with unmatched clarity and accuracy, providing clinicians with actionable insights to guide timely treatment decisions.
When we first found CAMLs, there were no publications on the clinical applications of CAMLs, despite the fact that they are very large and found in all the types of cancers we studied. Daniel L. Adams, currently the Chief Scientific Officer, performed a systematic analysis of those cells and found a spectrum of clinical applications, and he continues to find more clinical applications to help cancer patients.
By focusing on clinically relevant biomarkers and maintaining a strong foundation of scientific rigor, Creatv Bio is not only enhancing cancer diagnostics and early detection but also supporting ongoing monitoring of patient response to therapies. This pioneering approach positions the company as a trusted innovator, delivering solutions that hold the potential to transform patient care and redefine standards within the cancer diagnostics landscape.
Overcoming Barriers to Mainstream Adoption
While Creatv Bio has made significant strides in advancing cancer diagnostics, the journey toward mainstream adoption is met with complex challenges. A primary hurdle lies in building awareness among oncologists, researchers, and the general public about the potential of Cancer-Associated Macrophage-like Cells (CAMLs) as a breakthrough biomarker. Gaining this trust requires not only continued clinical validation but also effective communication of extensive data supporting the technology’s reliability and utility.
Regulatory pathways present another critical challenge. Bringing the LifeTracDx® blood test to broader markets demands rigorous FDA approvals, which require extensive clinical trials across multiple cancer types and multiple clinical applications. These trials involve substantial financial investment and time, often slowing the pace of bringing innovation to patients in need.
Under the leadership of Dr. Cha-Mei Tang, the company is taking strategic steps to address these barriers. By pursuing CLIA certifications and CAP approvals, Creatv MicroTech Bio is creating pathways to make its diagnostics available to patients even before full regulatory clearance. This approach reflects the company’s commitment to accelerating access to life-saving innovations while continuing to uphold the highest standards of scientific integrity and patient safety.
Milestones that Mark the Journey of Innovation
From a bold idea to a groundbreaking force in cancer diagnostics, Creatv Bio’s journey has been defined by transformative milestones and an unwavering commitment to saving lives.
- Pioneering Microfabrication Excellence
Developed precision-engineered CellSieve™ microfilters — enabling unmatched fast and gentle capturing of rare cells and providing high-quality images of those rare cells for cancer diagnostics. - Breakthrough Discovery
Identified Cancer-Associated Macrophage-like Cells (CAMLs), a novel biomarker found in 30+ cancer types, including early-stage cancers. - Collaborations
Partnered with leading universities, cancer centers, and pharmaceutical companies to advance clinical trials and drug development. -  LifeTracDx® Liquid Biopsy
Introduced a non-invasive blood test that provides early detection, continuous disease monitoring, companion diagnostics, and therapy response insights. - PD-L1 Companion Diagnostics by Blood Test
Immunotherapy works when PD-L1 expression on the tumor is high. Unlike other PD-L1 companion diagnostics, LifeTracDx® liquid biopsy does not require tissue. This is very useful because PD-L1 expression often changes during a variety of therapies. - Regulatory Progress
Achieved CLIA certification for its first diagnostic test, with CAP approvals in progress — paving the way for broader accessibility.
Industry Recognition
Honored with prestigious awards, including:
- ICE Award from TEDCO (2013)
- Incubator Company of the Year (2013)
- Bioscience Company of the Year, Montgomery Small Business Awards (2013)
- Inducted into Marquis Who’s Who (2023) – Read More
- Featured in Fortune Magazine (2024) – View Feature
- Induction into The Inner Circle Continental Who’s Who (2025) – See Highlight
LifeTracDx®: Transforming Liquid Biopsy for Better Cancer Care
At the heart of Creatv MicroTech Bio’s innovation is its flagship solution, LifeTracDx®, a liquid biopsy platform redefining how cancer is detected, monitored, and managed. Built on the company’s proprietary CellSieve™ microfilter technology, LifeTracDx® enables the efficient capture and analysis of rare cancer-related cells from a simple blood draw. This process removes red and most white blood cells within minutes, allowing for clear visualization and accurate identification of clinically significant cells, including Cancer-Associated Macrophage-like Cells (CAMLs) and circulating tumor cells (CTCs).
What sets LifeTracDx® apart is its ability to deliver actionable insights throughout the patient journey. It supports early detection, providing critical diagnostic information even in the initial stages of cancer across multiple types. Beyond detection, the platform facilitates determination of treatment response, changes in various biomarker expressions, determination of PD-L1 expression, continuous monitoring, enabling clinicians to evaluate disease progression in real time, without the need for repeated invasive biopsies, determine disease progression earlier than imaging, detection of minimal residual disease at the end of therapy, and determine cancer recurrence.
Through extensive collaborations with cancer centers, universities, and pharmaceutical companies, LifeTracDx® has demonstrated its versatility across research and clinical applications. By combining precision engineering with deep biological insight, Creatv Bio is empowering oncologists with reliable, non-invasive tools to make faster, more informed decisions—helping patients receive timely, personalized care.
Harnessing Advanced Technologies for Precision Diagnostics
Creatv MicroTech integrates state-of-the-art technologies to enhance the accuracy, efficiency, and scalability of its diagnostic solutions. The company’s proprietary microfabrication expertise underpins its innovative platforms, enabling the precise capture and analysis of rare cells with unparalleled clarity. By incorporating advanced imaging systems and data-driven analytics, Creatv MicroTech ensures that clinicians receive high-quality, actionable insights that support timely and informed decisions in cancer care.
Under the guidance of Dr. Cha-Mei Tang, the company continues to refine its processes by leveraging automation and precision engineering to optimize workflows. This approach not only accelerates diagnostic turnaround times but also maintains consistent performance across research and clinical applications. These advancements strengthen the clinical utility of LifeTracDx®, positioning it as a reliable tool for early detection, continuous monitoring, and therapy response assessment, ultimately driving better outcomes for patients worldwide.
Paving the Path to Global Leadership in Cancer Diagnostics
Over the next five years, Creatv Bio envisions establishing itself as a global leader in precision oncology diagnostics. Building on the success of its LifeTracDx® platform, the company plans to advance its regulatory journey by initiating multiple FDA approval processes, beginning with breast cancer applications in 2025. These approvals will serve as the foundation for expanding clinical use across additional cancer types, ensuring broader access to its innovative liquid biopsy solutions.
Strategic efforts will also focus on securing reimbursement pathways, a critical step in reducing the financial burden on patients and enabling widespread adoption of LifeTracDx® in clinical practice. Recognizing the importance of global collaboration, Creatv Bio aims to form strong international partnerships to bring its cutting-edge technologies to healthcare systems worldwide, without directly commercializing outside the United States.
Under the leadership of Dr. Cha-Mei Tang, the company remains committed to accelerating innovation, expanding accessibility, and transforming cancer diagnostics into a tool that not only saves lives but redefines how cancer is detected, monitored, and treated on a global scale.
Redefining the Future of Cancer Diagnostics through Vision and Precision
- Revolutionizing Early Detection – Creatv Bio’s discovery of CAMLs enables highly sensitive cancer detection across more than 30 cancer types, including early stages.
- Innovation at the Core – The LifeTracDx® platform transforms liquid biopsy with real-time, non-invasive monitoring that guides personalized cancer care.
- Bridging Science and Accessibility – Strategic regulatory milestones, including CLIA certification and ongoing FDA pathways, are accelerating access to life-saving diagnostics.
- Technology-Driven Precision – Advanced microfabrication and AI-driven analytics ensure unmatched clarity and accuracy in capturing and analyzing rare cells.
- Global Vision, Local Impact – Guided by Dr. Tang’s leadership, Creatv MicroTech is building global collaborations to expand the reach of precision oncology worldwide.
